AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

BioAmicus Complete for Functional Gastrointestinal Symptoms in Infants Aged 0 to 24 Months

RecruitingNAAges 0 Days - 24 MonthsAllHaiphong University of Medicine and Pharmacy
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Infants often experience functional gastrointestinal symptoms (e.g., colic, excessive gas, regurgitation, constipation, or loose stools) that distress families and may reflect an imbalance of the gut microbiome. This study evaluates whether the multistrain probiotic BioAmicus Complete can improve caregiver-reported gastrointestinal symptoms in infants 0-24 months and is safe for use in this population. The primary assessment is the change in the Infant Gastrointestinal Symptom Questionnaire (IGSQ) total score from the start to the end of the study period. Secondary assessments include symptom domains (colic/regurgitation, stool frequency and consistency), caregiver quality of life, growth parameters (weight and length), health care utilization and antibiotic exposure, and overall safety/tolerability (adverse events and serious adverse events). Stool samples will be analyzed to explore c

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age 0-24 months at enrollment. * Infant has clinician-assessed functional gastrointestinal symptoms (e.g., colic/irritability, regurgitation, constipation, loose stools), judged suitable for study participation. * Parent or legal guardian provides written informed consent and agrees to comply with study procedures (questionnaires/diaries and sample collection, if applicable). * Caregivers agree to avoid other probiotic products during the study period, except as directed by the study team. Exclusion Criteria: * Major congenital gastrointestinal anomalies or known chronic gastrointestinal diseases requiring ongoing prescription therapy (e.g., Hirschsprung disease, inflammatory bowel disease, short-bowel syndrome). * Clinically unstable condition or severe/critical illness that could interfere with participation or safety in the opinion of the investigator. * Known or suspected primary or secondary immunodeficiency, or current immunosuppressive therapy. * History of severe allergy or hypersensitivity to components of the investigational product. * Recent use of systemic antibiotics within 14 days prior to baseline, or use of probiotic supplements within 14 days prior to baseline (per protocol). * Participation in another interventional clinical trial within 30 days prior to enrollment or during the study. * Any condition that, in the investigator's judgment, would make the participant unsuitable for the study or confound outcome assessments.
๐Ÿ’Š

What it tests

  • BioAmicus Complete
  • Usual Care (No Probiotic)
๐Ÿ“

Where

1 site
Clinical Trial and Bioequivalence Center
Haiphong, Vietnam
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy